1. Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome;J, Blunt R.; J, George A.; A, Hurlow R.; L, Strachan C.J.; J, Stuart;BrJ Haematol,1980
2. Treatment of vasospastic disease with prostaglandin E;C, Clifford P.; R, Martin M.F.; J, Sheddon E.; D, Kirby J.; N, Baird R.; A, Dieppe P.;Br Med J,1980
3. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controjled trial;F, Belch J.J.; K, Drury J.; H, Capell;Lancet,1983
4. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2) Br;M, Dowd P.; R, Martin M.F.; D, Cooke E.;J Dermatol,1982
5. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue Iloprost in man;Krause, W.; Th, Krais;Eur J Clin Pharmacol,1986